Scarica l'app Stockscreener
0.7901
8.46%
-0.073
Dopo l'orario di chiusura:
.75
-0.0401
-5.08%
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Jasper Therapeutics Q2 EPS of $(0.10) beats estimates - scanx.trade
Jasper Therapeutics (JSPR) narrows Q2 2026 loss, closes Kira deal and $132M PIPE - Stock Titan
Jasper Therapeutics Reports $2.8 Million Second-Quarter Net Loss - Quiver Quantitative
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates - Blockonomi
Jasper Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln - TradingView
Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) — 10-Q Summary - TradingView
Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition - Quiver Quantitative
Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M - Stock Titan
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - globenewswire.com
Piper Sandler Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $2 - Moomoo
Piper Sandler initiates Jasper Therapeutics stock at overweight By Investing.com - Investing.com Canada
$Jasper Therapeutics (JSPR.US)$ Goodbye - Moomoo
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC - The National Law Review
Jasper Therapeutics Inc (JSPR) Stock News Today - TradingKey
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives? - Kalkine Media
JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst - TipRanks
Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know - TipRanks
JSPR Q2'26 Earnings: EPS estimate is (0.25) USD - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therap - The National Law Review
Jasper Therapeutics Inc (JSPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kira Pharmaceuticals - The Pharma Letter
Jasper Therapeutics, Inc. announced that it has received $131.996211 million in funding from a group of investors - marketscreener.com
Jasper Therapeutics (JSPR) completes $131.9M Rule 506(b) private equity sale - Stock Titan
Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director - Stock Titan
Jasper Therapeutics (JSPR) awards 7,500 stock options to board director - Stock Titan
Jasper Therapeutics (JSPR) grants 7,500-share stock option to board director - Stock Titan
Jasper Therapeutics (JSPR) grants director option for 7,500 shares - stocktitan.net
Jasper Therapeutics Shareholders Back Board, Auditors, Pay Plan - TipRanks
Jasper Therapeutics (NASDAQ: JSPR) outlines 2026 director, auditor and pay votes - Stock Titan
Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition, Issues CVRs - TipRanks
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPRW - TradingView
Jasper Therapeutics Inc (JSPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jasper Therapeutics Inc (JSPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Earnings Date & Reports & Earnings News - TradingKey
Jasper Therapeutics Inc (JSPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jasper Therapeutics Inc (JSPR) Institutional Confidence - TradingKey
Jasper Therapeutics Inc (JSPR) Income Statement - TradingKey
Jasper Therapeutics Inc (JSPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.695|Chg%:+0.006 - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.690|Chg%:+0.002 - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.688|Chg%:-0.041 - TradingKey
Jasper Therapeutics Inc (JSPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jasper Therapeutics Inc (JSPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jasper Therapeutics Inc (JSPR) Cash Flow - TradingKey
JSPR|Jasper Therapeutics Inc|Price:0.650|Chg%:-0.038 - TradingKey
Jasper Therapeutics, Inc. Revenue Breakdown – NASDAQ:JSPR - TradingView
Jasper Therapeutics Market Sentiment - Benzinga España
Jasper Therapeutics Inc. (JSPR) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Enterprise value to EBITDA forward of Jasper Therapeutics, Inc. – NASDAQ:JSPRW - TradingView
Jasper Therapeutics (JSPR) CMO lists merger-based stock option awards - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Jasper Therapeutics COO Matthew E. Ros files initial beneficial ownership statement - Bitget
Form 4 Jasper Therapeutics Inc For: 22 July By Investing.com - Investing.com Canada
Jasper Therapeutics (JSPR) COO buys non-voting convertible preferred shares - Stock Titan
Jasper Therapeutics (JSPR) EVP outlines option and preferred stakes after Kira deal - Stock Titan
Jasper Therapeutics (JSPR) COO discloses merger-converted option stakes - Stock Titan
Form 4 Jasper Therapeutics Inc For: 21 July By Investing.com - Investing.com South Africa
Jasper Therapeutics director Patrick J. Crutcher files initial beneficial ownership statement - Bitget
Jasper Therapeutics (JSPR) director buys preferred stock, granted stock options - Stock Titan
Jasper Therapeutics (JSPR) director details common and preferred stake - Stock Titan
Jasper closes Kira deal, extends cash runway - MSN
Jasper Therapeutics (JSPR) holders outline 3,349,547-share stake after Kira deal - Stock Titan
Weekly Recap: 132M convertible raise and Kira merger, Nasdaq JSPR - TradingView
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):